Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kuemmel S, Rhiem K, Warm M, Fasching P, Just M, Hanusch C, Hackmann J, Blohmer JU, Furlanetto J, Nekljudova V, Von Minckwitz G, Loibl S (2018)
Publication Type: Conference contribution
Publication year: 2018
Publisher: OXFORD UNIV PRESS
City/Town: OXFORD
Pages Range: 60-60
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1093/annonc/mdy270.185
APA:
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C.,... Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). In ANNALS OF ONCOLOGY (pp. 60-60). Munich, DE: OXFORD: OXFORD UNIV PRESS.
MLA:
Untch, M., et al. "Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018. 60-60.
BibTeX: Download